Kiniksa Pharmaceuticals Ltd logo

KNSA

Kiniksa Pharmaceuticals Ltd

$15.76

Earnings Summary

Revenue
$0Mn
Net Profits
$-49.48Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Kiniksa Pharmaceuticals Ltd’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2021. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Kiniksa Pharmaceuticals Ltd’s net profit fell -87.3% since last year same period to $-49.48Mn in the Q1 2021. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd has generated 7.78% jump in its net profits since last 3-months.

Net Profit Margins:

Kiniksa Pharmaceuticals Ltd’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2021. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Kiniksa Pharmaceuticals Ltd post its latest quarter earnings

EPS Estimate Current Quarter
-0.32
EPS Estimate Current Year
-0.32

Highlights

EPS Estimate Current Quarter:

Kiniksa Pharmaceuticals Ltd’s earning per share (EPS) estimates for the current quarter stand at -0.32 - a -247.67% fall from last quarter’s estimates.

EPS Estimate Current Year:

Kiniksa Pharmaceuticals Ltd’s earning per share (EPS) estimates for the current year stand at -0.32.

Key Ratios

Key ratios of the Kiniksa Pharmaceuticals Ltd post its Q2 2022 earnings

Earning Per Share (EPS)
-0.29
Return on Assets (ROA)
-0.06
Return on Equity (ROE)
0.48

Highlights

Earning Per Share (EPS):

Kiniksa Pharmaceuticals Ltd’s earning per share (EPS) jumped 52.46% since last year same period to -0.29 in the Q2 2022. This indicates that the Kiniksa Pharmaceuticals Ltd has generated 52.46% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kiniksa Pharmaceuticals Ltd’s return on assets (ROA) stands at -0.06.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kiniksa Pharmaceuticals Ltd’s return on equity (ROE) stands at 0.48.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.43
-0.36
16.28%
2022-08-04
-0.46
-0.29
36.26%

Company Information

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of assets, ARCALYST, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases.

Organisation
Kiniksa Pharmaceuticals Ltd
Headquarters
Clarendon House, Hamilton, Bermuda, HM 11
Employees
215
Industry
Health Technology

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*